Search This Blog

Wednesday, September 28, 2016

Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study

Pivotal ARISE Study of Erenumab in Episodic Migraine Prevention Met Primary Endpoint
People With Episodic Migraine Experience up to 14 Days of Migraine Each Month and Lose a Substantial Part of Their Lives to Migraine
Erenumab Co-Developed by Amgen and Novartis

Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.